View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 7, 2016updated 13 Jul 2022 10:15am

Reverse Logistics: Managing drug return and destruction

Henry Kerali examines the importance of having a strategy in place when destroying investigational products

By Staff Writer

When a clinical trial draws to its conclusion, returning and destroying investigational products (IPs) is often an overlooked consideration in the drug development process.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Even though IPs are destroyed after a clinical trial, the reconciliation and disposal of drugs is a critical phase that needs to be planned even before a trial begins. When it comes to reverse logistics, a thorough process must be put in place where the sponsor can account for the IP from the time it’s been produced to the point upon receiving a certificate of destruction.

Regardless of a clinical trial’s size, drug accountability must be completed at the close of the study. This may involve accountability all the way down to the individual dose level. Even controlled substances, for instance, require meticulous reconciliation down to the tablet level. Therefore, returned IPs must be efficiently processed and detailed records must be maintained.

If the same framework applied at the start of the study isn’t carried out to its conclusion, companies risk encountering regulatory issues further down the line. Without a plan in place such complications can hamper a trial sponsor’s ability to end their study on time. What’s more, improper or untimely drug accountability can also lead to flawed data, a delayed time to market, and increased costs. The consequences of not performing this accountability can cost customers time, money, and can delay future profits.

So going forward, here are five key things to consider that can help ease the process of shifting drugs back to the sender:

  • Keep transit points to a minimum – if possible, have your IP moved from the site directly back to your destruction vendor. The fewer hands that are involved, the less convoluted the process could be
  • Sponsors must be sure to use a vendor that uses a secure on-site reconciliation process to avoid future queries, such as, missing or lost packages
  • Assess packaging and site supply strategies to avoid stock overload of stock at investigator sites
  • Monitor stability data to avoid expired stock at site – minimise the amount of returns you have if you continue to collect stability data
  • Prepare a trusted “cradle to grave” reconciliation method from the start of your study. This will enable destruction as fast as possible

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena